Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7470933 | 0.90 | LTA4H (0.51) | TSHRACHECYP2D6MEN1KMT2A | |
| SCHEMBL5562683 | 0.83 | LTA4H (0.49) | TSHRACHECYP2D6MEN1KMT2A | |
| SCHEMBL5562676 | 0.83 | LTA4H (0.49) | TSHRACHECYP2D6MEN1KMT2A | |
| SCHEMBL3491795 | 0.82 | LTA4H (0.61) | ACHECYP2D6LTA4HTACR1SIGMAR1 | |
| SCHEMBL18325 | 0.82 | LTA4H (0.61) | ACHECYP2D6LTA4HTACR1SIGMAR1 | |
| SCHEMBL24350 | 0.82 | LTA4H (0.61) | ACHECYP2D6LTA4HTACR1SIGMAR1 | |
| SCHEMBL13595851 | 0.80 | ACHE (0.61) | TSHRACHECYP2D6MEN1KMT2A | |
| Piperazine SCHEMBL6099611 | 0.79 | SIGMAR1 (0.58) | TSHRCYP2D6MEN1KMT2ALTA4H | |
| SCHEMBL5361052 | 0.76 | LTA4H (0.58) | ACHECYP2D6MEN1KMT2ALTA4H | |
| SCHEMBL6099454 | 0.76 | LTA4H (0.58) | ACHECYP2D6MEN1KMT2ALTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993760-B2 | Rock inhibitors and uses thereof | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-03-31 | — | — | US | disclosed |
| US-20090318684-A1 | ROCK INHIBITORS AND USES THEREOF | UNIVERSITY OF SOUTH FLORIDA (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2008079945-A2 | ROCK INHIBITORS AND USES THEREOF | UNIVERSITY OF SOUTH FLORIDA (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318684-A1 | ROCK INHIBITORS AND USES THEREOF | ROCK1, ROCK2, CIT | TSHR 4175/4885ACHE 1718/4885CYP2D6 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.